SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) and Mayo Clinic announced today that they have signed a diagnostic collaborative agreement to enable the co-development of molecular diagnostic tests for the study of complex diseases. The agreement recognizes the strengths of both organizations. Illumina will contribute its VeraCode™ technology and development expertise for the BeadArray™ and BeadXpress™ instrument platforms. Mayo Clinic will bring broad knowledge in clinical practice and patient outcome management along with proficiency in establishing clinical utility of new diagnostic technologies. In addition, Mayo’s ability to discover and validate biomarkers offers the potential for both parties to implement important new clinical tests.
